Intravenous Immunoglobulin (IVIG) therapy is an immunomodulatory treatment derived from pooled human plasma that has been explored for various neurodegenerative diseases. IVIG contains polyclonal IgG antibodies and multiple immunomodulatory factors that may provide neuroprotective effects.
| Property |
Value |
| Treatment Name |
Intravenous Immunoglobulin (IVIG) |
| Trade Names |
Octagam, Privigen, Gamunex, Flebogamma |
| Mechanism |
Immunomodulation, anti-inflammatory |
| Administration |
Intravenous infusion |
| Dosing |
0.4-2 g/kg/month |
IVIG is composed of:
- Polyclonal IgG (95-98%): Main therapeutic component
- IgA and IgM (trace): May contribute to effects
- Soluble cytokines: IL-1RA, IL-10, TGF-β
- Anti-idiotype antibodies: Neutralize pathogenic antibodies
- Natural antibodies: Polyreactive IgG
- Fc Receptor Modulation: Blocks Fcγ receptors on macrophages
- Cytokine Regulation: Suppresses pro-inflammatory cytokines
- T-cell Modulation: Alters T-cell function and activation
- Complement Inhibition: Blocks complement activation
- Neutralizes Pathogenic Antibodies: Anti-idiotype antibodies
- Reduces Autoantibody Production: Modulates B-cell function
- Inhibits Complement: Prevents membrane attack complex
- Promotes Anti-inflammatory Cytokines: Increases IL-10, TGF-β
- Neurotrophic Factors: Contains GDNF, BDNF-like activity
- Membrane Protection: May protect neuronal membranes
- Synaptic Function: Improves synaptic plasticity in some models
- Rationale: Immunomodulation, anti-Aβ effects
- Evidence: Mixed results from clinical trials
- Status: Investigational, not FDA-approved
- Dosing: 0.4-2 g/kg monthly
- Rationale: Neuroinflammation reduction, α-synuclein clearance
- Evidence: Small trials showed mixed results
- Status: Investigational
- Combination: May enhance dopaminergic therapy
- Rationale: Autoimmune neuropathy
- Evidence: First-line treatment (with plasma exchange)
- Status: FDA-approved for GBS
- Efficacy: Accelerates recovery
- Rationale: Autoimmune demyelination
- Evidence: Effective maintenance therapy
- Status: FDA-approved for CIDP
- Dosing: Maintenance every 3-4 weeks
- Rationale: Conduction block from autoantibodies
- Evidence: Effective in most patients
- Status: First-line therapy
- Response Rate: 70-80%
- Rationale: Neuroinflammation, immune dysregulation
- Evidence: Clinical trials showed minimal benefit
- Status: Not approved for ALS
- Investigation: Ongoing combination approaches
- Headache
- Flu-like symptoms
- Chills
- Nausea
- Fatigue
- Mild fever
- Aseptic meningitis
- Hemolytic anemia
- Thromboembolic events
- Acute renal failure
- Severe headache
- Anaphylaxis (IgA deficiency)
- Stevens-Johnson syndrome
- Serum sickness
- Transfusion-related acute lung injury (TRALI)
- IgA deficiency (risk of anaphylaxis)
- Severe renal impairment
- Hypercoagulable states
- History of thromboembolism
- Severe heart failure
- Live vaccines: May impair vaccine response
- Immunosuppressants: Additive immunosuppression
- ACE inhibitors: Increased risk of aseptic meningitis
- Anticoagulants: Additive thrombosis risk
- Baseline: IgA levels, renal function, liver function
- During treatment: Blood counts, renal function
- For adverse effects: Vital signs during infusion
- Infusion rate: Start slow, titrate up
- Premedication: Acetaminophen, antihistamine
- Hydration: Important for renal clearance
- Responsive conditions: GBS, CIDP, MMN
- Investigational: AD, PD, ALS
- Not effective: MS (relapsing-remitting)
- IVIG in neurodegenerative disease - Neurology (2020)
- IVIG mechanisms of action - J Clin Immunol (2019)
- IVIG for Alzheimer's disease - Alzheimer's Dement (2018)
- IVIG in Parkinson's disease - Mov Disord (2017)
- IVIG for CIDP - Lancet Neurol (2016)
The study of Ivig Therapy For Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.